The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued positive opinions for Celltrion's (KRX:068270) biosimilars Eydenzelt (aflibercept), Stoboclo and Osenvelt (denosumab), and Avtozma (tocilizumab), Celltrion said Monday.
Eydenzelt, comparable to Eylea, targets retinal disorders such as wet AMD and diabetic macular edema. Stoboclo and Osenvelt are at par with Prolia and Xgeva for osteoporosis and cancer-related conditions. Avtozma is comparable to RoActemra for rheumatoid arthritis and other inflammatory diseases, the press release said.
The products require European Commission approval for marketing in the European Union.
Shares of Celltrion rose more than 1% in recent trade on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.